Biogen reported better-than-expected first-quarter earnings and revenue on Wednesday, and trimmed its full-year earnings outlook, citing charges related to business development activity.
Investor's Business Daily on MSN
Biogen had a nearly perfect sales sweep, but one beat really stood out
Biogen obliterated Wall Street's first-quarter expectations Wednesday, helped by a nearly perfect sales beat sweep from its growth products.
Biogen BIIB reported upbeat earnings for the first quarter on Wednesday. The company posted quarterly earnings of $3.57 per ...
Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer's market ...
Biogen (BIIB) stock is in focus as the company beats forecasts with its Q1 2026 financials and trims its full-year earnings ...
Biogen cut its full-year profit forecast on Wednesday as it booked acquisition-related charges, although its first-quarter ...
Biogen (NASDAQ:BIIB) is gearing up to announce its quarterly earnings on Thursday, 2025-10-30. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...
Biogen is poised to announce its first-quarter results next week, and analysts predict a marginal drop in the company’s ...
Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair CAMBRIDGE, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: ...
Biogen’s growth was expected to stay flat through the 2030s. A key acquisition and busy late-stage pipeline have relieved the ...
Biogen Inc. (NASDAQ:BIIB) is one of the best stem cell therapy stocks to buy. On April 22, Biogen Inc. (NASDAQ:BIIB) was ...
Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights Collaboration broadens Biogen’s rare disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results